Gastrointestinal Cancer | Specialty

Recent Approvals, Collaborative Care Model Spark Change in HCC Treatment

March 2nd 2020

Michael R. Charlton, MD, MBBS, discusses the evolution of hepatocellular carcinoma treatment.

Breathing New Life Into Chemotherapy

March 2nd 2020

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

Dr. Salem on Locoregional Therapy Versus Systemic Therapy in HCC

March 2nd 2020

Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.

Dr. Singal on the Importance of Early Diagnosis in HCC

March 2nd 2020

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

Immunotherapy Combinations Show Promise in Advanced HCC

March 2nd 2020

Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.

Evidence Illustrates Multidisciplinary Care Is Standard in HCC

March 1st 2020

Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.

Pillai Reflects on Achieved Goals at Inaugural HCC-TAG Conference

March 1st 2020

Anjana Pillai, MD, reflects on the first annual HCC-TAG Conference, her journey into treating patients with liver cancer, and remaining challenges in the paradigm

Dr. Hoshida on Molecular Subtyping in HCC

March 1st 2020

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

Dr. Pinato on Biomarker Challenges in HCC

March 1st 2020

David J. Pinato, MD, PhD, discusses the lack of biomarkers in hepatocellular carcinoma.

Burst of Targeted Agents Leads to Transformed HCC Paradigm

February 29th 2020

Richard S. Finn, MD, reflects on data from the phase III REFLECT, RESORCE, CELESTIAL, and REACH-2 trials in hepatocellular carcinoma.

Biomarker Hunt Gains Traction Among Therapeutic Advances in HCC

February 29th 2020

David J. Pinato, MD, PhD, highlights the clinical and biological challenges in identifying biomarkers in hepatocellular carcinoma, and the potential introduction of biomarkers in the future.

Experts Share Common Misconceptions in Their Fields

February 29th 2020

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Dr. Parikh on the Importance of Multidisciplinary Care in HCC

February 29th 2020

Neehar Parikh, MD, discusses the importance of multidisciplinary care in the treatment of patients with hepatocellular carcinoma.

Dr. Abou-Alfa on Optimizing Treatment Selection in HCC

February 29th 2020

Ghassan K. Abou-Alfa, MD, discusses ways to optimize treatment selection for patients with hepatocellular carcinoma.

Abou-Alfa Hails "Positive and Disruptive" Impact of Novel Combinations in HCC

February 29th 2020

Findings from the phase III IMbrave 150 trial represented the first time a treatment outperformed sorafenib for overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC), and the HCC world was understandably excited, said Ghassan K. Abou-Alfa, MD.

The Future of HCC Management

February 28th 2020

Etiologic Reponses to Treating Hepatitis B/C-Related HCC

February 28th 2020

Therapy Options for Hepatitis B/C-Related HCC

February 28th 2020

Treatment Approach After IMpower150 Regimen

February 28th 2020

Relapsed/Refractory HCC: Third-Line Approach

February 28th 2020